U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07893197) titled 'Ceritinib Treatment for Recurrent Meningiomas' on Oct. 07.
Brief Summary: In this study, patients with recurrent grade I and grade II meningiomas will receive a daily dose of ceritinib for abour two years. Patients will visit the clinic on average about every 2 months for assessments. The objectives of the trial are 1) to analyse if ceritinib can slow or stop tumor recurrence and progression; 2)to investigate how safe ceritinib is in this group of patients.
Study Start Date: Jan., 2027
Study Type: INTERVENTIONAL
Condition:
Recurrent Meningioma, Grade I and Grade II
Intervention:
DRUG: Ceritinib
450mg daily with food
Recruitm...